+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
KRAS Inhibitor Market - Global Forecast 2026-2032- Product Image
KRAS Inhibitor Market - Global Forecast 2026-2032- Product Image
Sale

KRAS Inhibitor Market - Global Forecast 2026-2032

  • Report

  • 199 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6125434
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The KRAS Inhibitor Market is projected to reach USD 968.58 Million in 2026. It is expected to continue growing at a CAGR of 4.74%, reaching USD 1.27 Billion by 2032.

KRAS Inhibitors: Executive Overview

KRAS inhibitors are targeted oncology therapies designed to block signaling from mutated KRAS proteins, which can drive tumor growth. The field is advancing through mutation-specific drug design, improved biomarker testing, and clinical research focused on colorectal, lung, pancreatic, and other solid tumors. Progress remains dependent on demonstrating durable benefit, managing resistance, and identifying patients whose tumors are most likely to respond.

Precision Oncology Is Reshaping KRAS Inhibitor Development

The landscape is shifting from broad pathway inhibition toward selective targeting of individual KRAS variants and molecular states. Companion diagnostics, liquid biopsy, next-generation sequencing, and longitudinal disease monitoring are becoming increasingly important for confirming eligibility and tracking emerging resistance. Development strategies are also placing greater emphasis on combination regimens, including approaches that address downstream signaling, immune activity, or parallel resistance pathways.

Artificial Intelligence Accelerates Discovery and Clinical Decision-Making

Artificial intelligence can support KRAS inhibitor research by identifying candidate binding sites, modeling protein conformations, prioritizing chemical compounds, and analyzing large genomic and clinical datasets. In development programs, machine-learning methods may help refine patient selection, detect response patterns, and characterize resistance mechanisms. Its value depends on high-quality, representative data, transparent validation, and clinical oversight; AI does not replace laboratory evidence or prospective clinical evaluation.

Regional Dynamics Differ Across Oncology Systems

North America benefits from advanced oncology infrastructure, active translational research, and established molecular testing pathways. Europe combines strong academic networks with country-level differences in reimbursement, diagnostics access, and regulatory implementation. Asia-Pacific is supported by expanding precision-medicine capabilities, while adoption varies across health systems. Latin America is progressing through selected specialist centers but continues to face access and testing constraints. The Middle East is building genomics and oncology capacity, particularly in major hubs, whereas Africa remains more constrained by diagnostic availability, treatment financing, and specialist workforce capacity.

International Groups Shape Evidence, Access, and Coordination

ASEAN markets present varied regulatory and healthcare environments, making regional coordination and diagnostic standardization important. BRICS countries combine substantial scientific and clinical capabilities with uneven access and infrastructure. The European Union benefits from cross-border research and regulatory cooperation, although national health-technology assessment and reimbursement decisions remain distinct. G7 members generally possess mature oncology ecosystems and strong research networks. GCC states are expanding specialized healthcare and genomic medicine programs. NATO members encompass diverse health systems, but collaboration in biomedical research and resilient healthcare planning can support broader preparedness.

Country Readiness Varies by Testing and Treatment Infrastructure

The United States and Canada have established precision-oncology networks, while the United Kingdom, France, Germany, Italy, and Spain combine advanced clinical research with differing reimbursement and diagnostic pathways. Australia and Japan have strong specialist care and research capabilities. China and South Korea are expanding genomic testing, drug development, and oncology infrastructure. India is strengthening precision-medicine capacity, though affordability and geographic access remain important considerations. Brazil, Mexico, and Russia have major tertiary-care centers but face regional variation in molecular testing, specialist availability, and treatment access.

Priorities for Leaders in the KRAS Inhibitor Field

Industry leaders should align drug development with validated mutation-specific biomarkers and deploy robust testing strategies early in the care pathway. Evidence plans should measure durability, resistance, quality of life, and clinically meaningful outcomes across diverse populations. Partnerships with diagnostic providers, academic centers, and health systems can improve sample access and implementation. Organizations should also prepare region-specific access strategies, strengthen real-world evidence capabilities, use AI under rigorous governance, and design combinations around clearly supported biological hypotheses rather than broad empirical screening alone.

Methodology for a Reliable KRAS Inhibitor Assessment

This executive summary is based on a structured review framework covering KRAS biology, therapeutic mechanisms, clinical development themes, biomarker and diagnostic requirements, resistance research, health-system readiness, and regional access considerations. Insights should be validated against peer-reviewed publications, clinical-trial registries, regulatory documents, treatment guidelines, pharmacovigilance sources, and national health-policy materials. Findings are presented qualitatively and intentionally exclude market estimates, market shares, forecasts, and company-specific claims.

Conclusion: Biomarker Precision and Access Will Define Progress

KRAS inhibitor development is moving toward more precise molecular targeting, combination strategies, and data-informed treatment selection. Sustainable progress will require evidence of durable clinical value, reliable identification of eligible patients, proactive resistance management, and equitable implementation across health systems. Leaders that integrate translational science, diagnostics, responsible AI, and regionally appropriate access planning will be best positioned to advance outcomes in KRAS-driven cancers.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. KRAS Inhibitor Market, by Indication
7.1. Introduction
7.2. Colorectal Cancer
7.3. Non-Small Cell Lung Cancer
7.4. Pancreatic Cancer
8. KRAS Inhibitor Market, by Mechanism Of Action
8.1. Introduction
8.2. Allosteric Inhibitors
8.3. Covalent Inhibitors
8.4. Non-Covalent Inhibitors
9. KRAS Inhibitor Market, by Mutation Type
9.1. Introduction
9.2. G12C
9.3. G12D
9.4. G12V
10. KRAS Inhibitor Market, by Dosage Form
10.1. Introduction
10.2. Injectable Solutions
10.3. Oral Tablets
11. KRAS Inhibitor Market, by End User
11.1. Introduction
11.2. Cancer Care Centers
11.3. Hospitals
11.4. Retail Pharmacies
11.5. Specialty Clinics
12. KRAS Inhibitor Market, by Distribution Channel
12.1. Introduction
12.2. Offline
12.3. Online
13. KRAS Inhibitor Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. KRAS Inhibitor Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. KRAS Inhibitor Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Amgen
17.2. AnBogen Therapeutics
17.3. Applied Pharmaceutical Science
17.4. AstraZeneca
17.5. Biond Biologics
17.6. Boehringer Ingelheim
17.7. BridgeBio Oncology Therapeutics
17.8. Bristol Myers Squibb
17.9. Cardiff Oncology, Inc.
17.10. Deciphera Pharmaceuticals
17.11. Eli Lilly
17.12. Elicio Therapeutics
17.13. Erasca
17.14. Frontier Medicines
17.15. GenFleet Therapeutics
17.16. Gritstone Bio
17.17. Immuneering Corporation
17.18. Innovent Bio
17.19. InventisBio
17.20. Jacobio Pharmaceuticals
17.21. Jiangsu Hansoh Pharmaceutical
17.22. Jiangsu Hengrui Medicine Co.
17.23. Merck
17.24. Mirati Therapeutics
17.25. Novartis
17.26. Quanta Therapeutics
17.27. Revolution Medicines
17.28. Roche
17.29. Suzhou Zelgen Biopharmaceuticals
17.30. Verastem Oncology
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global KRAS Inhibitor Market, Years Considered for the Study
FIGURE 2. Global KRAS Inhibitor Market, Research Design
FIGURE 3. Global KRAS Inhibitor Market, Research Framework
FIGURE 4. Global KRAS Inhibitor Market, Data Triangulation
FIGURE 5. Global KRAS Inhibitor Market Size, 2017-2032 (USD Million)
FIGURE 6. Global KRAS Inhibitor Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 7. Global KRAS Inhibitor Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global KRAS Inhibitor Market Size, by Mechanism Of Action, 2025 vs 2032 (%)
FIGURE 9. Global KRAS Inhibitor Market Size, by Mechanism Of Action, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global KRAS Inhibitor Market Size, by Mutation Type, 2025 vs 2032 (%)
FIGURE 11. Global KRAS Inhibitor Market Size, by Mutation Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global KRAS Inhibitor Market Size, by Dosage Form, 2025 vs 2032 (%)
FIGURE 13. Global KRAS Inhibitor Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global KRAS Inhibitor Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global KRAS Inhibitor Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global KRAS Inhibitor Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 17. Global KRAS Inhibitor Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global KRAS Inhibitor Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global KRAS Inhibitor Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global KRAS Inhibitor Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global KRAS Inhibitor Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global KRAS Inhibitor Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global KRAS Inhibitor Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global KRAS Inhibitor Market Segmentation & Coverage
TABLE 2. Global KRAS Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 3. Global KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 4. Global Colorectal Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Colorectal Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Colorectal Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Non-Small Cell Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Non-Small Cell Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Non-Small Cell Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Pancreatic Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Pancreatic Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Pancreatic Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 14. Global Allosteric Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Allosteric Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Allosteric Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Covalent Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Covalent Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Covalent Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Non-Covalent Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Non-Covalent Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Non-Covalent Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 24. Global G12C Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global G12C Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global G12C Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global G12D Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global G12D Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global G12D Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global G12V Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global G12V Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global G12V Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 34. Global Injectable Solutions Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Injectable Solutions Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Injectable Solutions Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Oral Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Oral Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Oral Tablets Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 41. Global Cancer Care Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Cancer Care Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Cancer Care Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 54. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global KRAS Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Asia-Pacific KRAS Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Asia-Pacific KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 63. Asia-Pacific KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 64. Asia-Pacific KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 68. North America KRAS Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. North America KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 70. North America KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 71. North America KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 72. North America KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 73. North America KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 74. North America KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 75. Latin America KRAS Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Latin America KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 77. Latin America KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 78. Latin America KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 79. Latin America KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 80. Latin America KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 81. Latin America KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 82. Europe KRAS Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Europe KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 84. Europe KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 85. Europe KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 86. Europe KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 87. Europe KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 88. Europe KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 89. Middle East KRAS Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Middle East KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 91. Middle East KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 92. Middle East KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 93. Middle East KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 94. Middle East KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 95. Middle East KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 96. Africa KRAS Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Africa KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 98. Africa KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 99. Africa KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 100. Africa KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 101. Africa KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 102. Africa KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 103. Global KRAS Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. ASEAN KRAS Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. ASEAN KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 106. ASEAN KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 107. ASEAN KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 108. ASEAN KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 109. ASEAN KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 110. ASEAN KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 111. GCC KRAS Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. GCC KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 113. GCC KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 114. GCC KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 115. GCC KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 116. GCC KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 117. GCC KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 118. European Union KRAS Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. European Union KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 120. European Union KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 121. European Union KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 122. European Union KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 123. European Union KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 124. European Union KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 125. BRICS KRAS Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 126. BRICS KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 127. BRICS KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 128. BRICS KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 129. BRICS KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 130. BRICS KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 131. BRICS KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 132. G7 KRAS Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. G7 KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 134. G7 KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 135. G7 KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 136. G7 KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 137. G7 KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 138. G7 KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 139. NATO KRAS Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 140. NATO KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 141. NATO KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 142. NATO KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 143. NATO KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 144. NATO KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 145. NATO KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 146. Global KRAS Inhibitor Market Size, by Country, 2017-2032 (USD Million)
TABLE 147. United States KRAS Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 148. United States KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 149. United States KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 150. United States KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 151. United States KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 152. United States KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 153. United States KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 154. Canada KRAS Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 155. Canada KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 156. Canada KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 157. Canada KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 158. Canada KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 159. Canada KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 160. Canada KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 161. Mexico KRAS Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 162. Mexico KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 163. Mexico KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 164. Mexico KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 165. Mexico KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 166. Mexico KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 167. Mexico KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 168. Brazil KRAS Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 169. Brazil KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 170. Brazil KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 171. Brazil KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 172. Brazil KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 173. Brazil KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 174. Brazil KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 175. United Kingdom KRAS Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 176. United Kingdom KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 177. United Kingdom KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 178. United Kingdom KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 179. United Kingdom KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 180. United Kingdom KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 181. United Kingdom KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 182. Germany KRAS Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 183. Germany KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 184. Germany KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 185. Germany KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 186. Germany KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 187. Germany KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 188. Germany KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 189. France KRAS Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 190. France KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 191. France KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 192. France KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 193. France KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 194. France KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 195. France KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 196. Russia KRAS Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 197. Russia KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 198. Russia KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 199. Russia KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 200. Russia KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 201. Russia KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 202. Russia KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 203. Italy KRAS Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 204. Italy KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 205. Italy KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 206. Italy KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 207. Italy KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 208. Italy KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 209. Italy KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 210. Spain KRAS Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 211. Spain KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 212. Spain KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 213. Spain KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 214. Spain KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 215. Spain KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 216. Spain KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 217. China KRAS Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 218. China KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 219. China KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 220. China KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 221. China KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 222. China KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 223. China KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 224. India KRAS Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 225. India KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 226. India KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 227. India KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 228. India KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 229. India KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 230. India KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 231. Japan KRAS Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 232. Japan KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 233. Japan KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 234. Japan KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 235. Japan KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 236. Japan KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 237. Japan KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 238. Australia KRAS Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 239. Australia KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 240. Australia KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 241. Australia KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 242. Australia KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 243. Australia KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 244. Australia KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 245. South Korea KRAS Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 246. South Korea KRAS Inhibitor Market Size, by Indication, 2017-2032 (USD Million)
TABLE 247. South Korea KRAS Inhibitor Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 248. South Korea KRAS Inhibitor Market Size, by Mutation Type, 2017-2032 (USD Million)
TABLE 249. South Korea KRAS Inhibitor Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 250. South Korea KRAS Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 251. South Korea KRAS Inhibitor Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 252. Global KRAS Inhibitor Market Share, by Key Player, 2025
TABLE 253. Global KRAS Inhibitor Market, Key Experts

Companies Mentioned

  • Amgen
  • AnBogen Therapeutics
  • Applied Pharmaceutical Science
  • AstraZeneca
  • Biond Biologics
  • Boehringer Ingelheim
  • BridgeBio Oncology Therapeutics
  • Bristol Myers Squibb
  • Cardiff Oncology, Inc.
  • Deciphera Pharmaceuticals
  • Eli Lilly
  • Elicio Therapeutics
  • Erasca
  • Frontier Medicines
  • GenFleet Therapeutics
  • Gritstone Bio
  • Immuneering Corporation
  • Innovent Bio
  • InventisBio
  • Jacobio Pharmaceuticals
  • Jiangsu Hansoh Pharmaceutical
  • Jiangsu Hengrui Medicine Co.
  • Merck
  • Mirati Therapeutics
  • Novartis
  • Quanta Therapeutics
  • Revolution Medicines
  • Roche
  • Suzhou Zelgen Biopharmaceuticals
  • Verastem Oncology

Related Topics

Related Reports

KRAS Inhibitors - Market Size, Target Population, Competitive Landscape & Market Forecast - 2036 - Product Image

KRAS Inhibitors - Market Size, Target Population, Competitive Landscape & Market Forecast - 2036

  • Report
  • 120 Pages
  • Global
From
PROTAC-Based Cancer Therapeutics Market - Strategic Insights and Forecasts (2026-2031) - Product Image

PROTAC-Based Cancer Therapeutics Market - Strategic Insights and Forecasts (2026-2031)

  • Report
  • 151 Pages
  • Global
From
Therapeutic Applications of Nitric Oxide in Cancer and Inflammatory Disorders. Third International Conference on Therapeutic Application of Nitric Oxide in Cancer and Inflammatory Disorders - Product Image

Therapeutic Applications of Nitric Oxide in Cancer and Inflammatory Disorders. Third International Conference on Therapeutic Application of Nitric Oxide in Cancer and Inflammatory Disorders

  • Book
  • Global
Cancer Therapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Cancer Therapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 200 Pages
  • Global
From
Promising Cancer Therapeutic Drug Targets: Recent Advancements - Product Image

Promising Cancer Therapeutic Drug Targets: Recent Advancements

  • Book
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.